Federated Kaufmann Fund
VC Fund
Federated Kaufmann Fund is an investment management firm that specializes in the fields of mutual funds, managed accounts institutional, and separate accounts. IT offers equity, international, fixed income, alternative, and money market strategies.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Federated Kaufmann Fund invests in
BiotechnologyHealth CareMedicalTherapeuticsPharmaceutical
Stages Federated Kaufmann Fund invests in
Post-IPO EquitySeries CSeries BSeries EFunding Round
Countries Federated Kaufmann Fund invests in
United StatesSwitzerlandCanadaLatviaUnited Kingdom
Investment Focus
Industry
- Biotechnology 21 (60%)
- Health Care 16 (46%)
- Medical 8 (23%)
- Therapeutics 8 (23%)
- Pharmaceutical 7 (20%)
Stage
- Post-IPO Equity 25 (71%)
- Series C 3 (9%)
- Series B 2 (6%)
- Series E 2 (6%)
- Funding Round 1 (3%)
Country
- United States 28 (80%)
- Switzerland 2 (6%)
- Canada 1 (3%)
- Latvia 1 (3%)
- United Kingdom 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Minerva Neuroscience
|
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise,we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action. | $80M / Post-IPO Equity / Oct 21, 2025 | |
Rezolute
|
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. Rezolute is advancing a diversified portfolio including: RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with anabbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population. | $96.9M / Post-IPO Equity / Apr 23, 2025 | |
Regulus Therapeutics
|
Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteinsbut instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California. | $15M / Post-IPO Equity / Apr 13, 2023 | |
Fusion Pharmaceuticals
|
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.Fusion’s deepradiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity. | $60M / Post-IPO Equity / Feb 13, 2023 | |
|
Regulus Therapeutics
|
Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteinsbut instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California. | $34.6M / Post-IPO Equity / Nov 24, 2021 | |
Jasper Therapeutics
|
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $100M / Post-IPO Equity / Sep 27, 2021 | |
Archer
|
Archer is an aerospace company building an all-electric vertical takeoff and landing aircraft focused on improving mobility in cities. The company's mission is to advance the benefits of sustainable air mobility. Archer is designing, manufacturing, and operating a fully electric aircraft that can carry four passengers for 60 miles at speeds ofup to 150mph while producing minimal noise. Archer's team is based in the San Francisco Bay Area. | $600M / Post-IPO Equity / Sep 17, 2021 | |
Laronde
|
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $440M / Series B / Aug 30, 2021 | |
Hyzon Motors
|
Hyzon is a global supplier of hydrogen fuel cell-powered commercial vehicles, including heavy duty trucks, buses and coaches. | $400M / Post-IPO Equity / Jul 19, 2021 | |
AvePoint
|
AvePoint is a technology company providing infrastructure management software solutions for Microsoft SharePoint products and technologies. The company is also focusing on class big data management, governance, and compliance software solutions for next-generation social collaboration platforms.AvePoint markets with a unique solution thatcentralizes access and control of information assets residing in disparate collaboration and document management systems on-premises and in the cloud. The company's solutions and services aim to bring together business, IT, as well as compliance and risk officers to serve key business objectives such as big data, cloud integration, compliance, enterprise content management, and mobile data access monitoring.AvePoint was founded in 2001 and based out of Jersey City, NJ, serves more than 13,000 organizations in five continents across all industry sectors, with focused practices in the energy and utilities; financial services; healthcare and pharmaceuticals; and public sector industries. AvePoint is a Depth Managed Microsoft Gold Certified Application Development Partner and Gold Certified Collaboration and Content Partner, as well as a US Government GSA provider via strategic partnerships. | $140M / Post-IPO Equity / Jul 02, 2021 | |
| See all 35 investments → | |||
Co-Investors
Fidelity
6 deals together
Fidelity
6 deals together
Perceptive Advisors
6 deals together
BlackRock
5 deals together
OrbiMed
5 deals together
Woodline Partners
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Federated Kaufmann Fund invest in?
Federated Kaufmann Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series C stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Federated Kaufmann Fund last invest?
The most recent investment recorded for Federated Kaufmann Fund closed in Oct 2025. Shizune tracks 35 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
